Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants

E. C. Reed, R. A. Bowden, P. S. Dandliker, K. E. Lilleby, J. D. Meyers

Research output: Contribution to journalArticle

406 Scopus citations


Cytomegalovirus is life-threatening in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS), recipients of organ allografts, and neonates. The high incidence of cytomegalovirus infection and disease in recipients of bone marrow allograft and the 85% mortality rate associated with cytomegalovirus pneumonia makes this disease the leading infectious cause of death after allogeneic bone marrow transplant. Various animal models suggest the combination of an antiviral agent and passive immunotherapy with antibody is more effective for the treatment of viral infections than either modality alone, including a recent study that combined ganciclovir and anticytomegalovirus antiserum. The severity of cytomegalovirus pneumonia, the poor results obtained with previous regimens, and the lack of other modalities for the treatment of cytomegalovirus infection led us to treat 25 patients with allogeneic marrow transplants and proven cytomegalovirus pneumonia with the combination of ganciclovir and intravenous cytomegalovirus immunoglobulin in a consecutive entry trial.

Original languageEnglish (US)
Pages (from-to)783-788
Number of pages6
JournalAnnals of internal medicine
Issue number10
StatePublished - Jan 1 1988


ASJC Scopus subject areas

  • Internal Medicine

Cite this